African genomics is the missing piece in global drug development. Sub-Saharan African populations harbour more genetic variation than all other human populations combined, a direct consequence of humanity's evolutionary origins on the continent and complex patterns of population divergence and migration across Africa. Modern humans emerged in Africa around 150,000–200,000 years ago, and African populations subsequently underwent substantial internal differentiation, with divergence events occurring 130,000–90,000 years ago, before the major out-of-Africa dispersal roughly 60,000 years ago. This deep history of African population structure generated genetic diversity far exceeding that carried by the small founding populations that seeded global human populations. Despite this, African individuals represent roughly 2 percent of participants in genome-wide association studies (GWAS) as of 2022, according to analysis in Nature, a modest improvement from under 1.1 percent in 2021. That gap means that the genetic basis of disease, drug response, and adverse events in African-ancestry populations is systematically unknown, a scientific problem with immediate clinical and commercial consequences for any drug developer targeting global markets.
Africa's unmatched genetic diversity
The scale of genetic diversity in Africa is difficult to overstate. A person of European ancestry and a person of South Asian ancestry share more genetic similarity with each other than either does with the full range of variation present across African ethnic groups. The continent is home to more than 2,000 distinct ethnic groups, each with unique allele frequency patterns shaped by geography, migration history, disease exposure, and dietary environment.
This diversity has practical consequences for drug development. Variants that are rare in European populations, and therefore missed in large European GWAS, may be common in specific African populations and may have strong effects on drug metabolism, disease susceptibility, or treatment response. Conversely, variants assumed to be universal based on European data may be absent or functionally different in African-ancestry individuals.
The 1000 Genomes Project documented that African populations contain the largest number of unique genetic variants not found in any other continental group. Subsequent analyses have found that millions of common single-nucleotide polymorphisms (SNPs) catalogued across human populations are found exclusively in African individuals, with one study of just 426 people across 50 ethnolinguistic groups in Africa revealing more than 3 million previously unknown variants. Any drug targeting a pathway influenced by these variants, and many do, cannot be fully characterised without African genetic data.
The H3Africa Consortium: building genomic capacity
The H3Africa (Human Heredity and Health in Africa) Consortium was established in 2012 as a collaborative network of African scientists and institutions, funded primarily by the US National Institutes of Health and the Wellcome Trust. Its mandate was to build Africa-based genomic research capacity, generate large-scale genetic data from African populations, and ensure that African scientists lead and own the resulting research.
Over its first decade, H3Africa enrolled over 100,000 participants across more than 30 African countries, covering conditions including hypertension, diabetes, chronic kidney disease, stroke, and infectious diseases. The consortium established three regional biorepositories (in Nigeria, Uganda, and South Africa) and developed Africa-specific bioinformatics training programmes. Its data are deposited in the European Genome-phenome Archive and the African Genome Variation Project database, with controlled access for qualified researchers.
H3ABioNet, the bioinformatics network that operates alongside H3Africa, has trained hundreds of African bioinformaticians and healthcare professionals since its launch through face-to-face workshops and online courses across its nodes. Before H3ABioNet, most African genomic data had to be sent abroad for analysis, creating bottlenecks, data sovereignty concerns, and a brain drain. The network has established analysis nodes at institutions across the continent, enabling African scientists to process and interpret their own population's data.
The consortium's scientific output has been substantial. H3Africa studies have identified novel loci for hypertension in West African populations, characterised kidney disease variants common in Sub-Saharan Africa that are absent from European datasets, and mapped population structure across the continent with greater resolution than any prior project. Several findings have direct clinical relevance: hypertension genetic variants identified in H3Africa populations suggest different drug targets than those prioritised based on European GWAS.
Pharmacogenomics in African populations
Pharmacogenomics in Africa is where the scientific gap translates most directly into patient harm and missed commercial opportunity. Drug metabolism varies across populations because the enzymes that process most drugs, primarily the cytochrome P450 (CYP450) family, are encoded by highly polymorphic genes, and allele frequencies for loss-of-function and gain-of-function variants differ substantially across ancestry groups.
The CYP2D6 enzyme metabolises approximately 25 percent of all prescribed drugs. The frequency of CYP2D6 gene duplications, which can produce ultra-rapid metaboliser phenotypes and render standard doses ineffective, has been found in up to 29 percent of individuals in Ethiopian populations, compared to 1 to 2 percent in Northern European populations. Poor metaboliser phenotypes, which can cause drug accumulation and toxicity at standard doses, show different frequencies across West, East, and Southern African populations that diverge from European norms.
CYP2C19 is equally important for cardiovascular medicine. Clopidogrel, one of the world's most widely prescribed antiplatelet agents, is a prodrug activated by CYP2C19. Loss-of-function alleles that impair this activation are carried by approximately 12 to 18 percent of individuals of African ancestry, with additional Africa-enriched variants like CYP2C19*35, a no-function allele found at 3 to 6 percent frequency across Sub-Saharan African populations, contributing further variability that standard testing panels may miss. Trials that enrolled predominantly European populations systematically underestimated the prevalence of inadequate clopidogrel response in African-ancestry patients, contributing to years of clinical uncertainty about real-world effectiveness.
Warfarin dosing is another critical example. The dose required to achieve therapeutic anticoagulation varies by up to 10-fold across individuals, with a significant portion of this variation explained by variants in CYP2C9 and VKORC1. The frequency of low-dose VKORC1 variants is lower in African-ancestry populations than in European or East Asian populations, meaning African patients typically require higher warfarin doses, a finding that was missed for years because African patients were not included in the pharmacogenomic studies that informed dosing guidelines.
These are not edge cases. They represent systematic miscalibration of drug dosing guidelines for hundreds of millions of patients.
African biobanks and genomic infrastructure
Biobanks, collections of biological samples linked to clinical data, are the raw material of genomic research. Africa's biobank infrastructure has grown substantially since 2010, though it remains well below the scale needed to support population-level genomic studies.
54gene, a Nigerian genomics company founded in 2019, built one of the continent's first large-scale biobanks explicitly designed for pharmacogenomics research. The company partnered with hospitals across Nigeria to collect DNA samples and linked clinical data, with a focus on conditions including cancer, hypertension, and diabetes. By the end of 2019, it had collected samples from approximately 40,000 individuals, and the biobank grew substantially in subsequent years. The company subsequently restructured, but the scientific model it pioneered, African biobanking as a commercial and research asset, influenced the sector.
The African Genome Variation Project (AGVP), a collaboration between the Wellcome Sanger Institute and African institutions, has characterised genome-wide variation across 18 ethnically diverse groups from 8 African countries. Its data provide a reference panel specifically calibrated for African populations, essential for accurate GWAS analysis in African samples, which cannot rely on European reference panels without introducing systematic errors.
Rwanda, through the Rwanda Biomedical Centre, has developed centralised biobanking capacity linked to its nationwide OpenMRS electronic health record system. This linkage of genetic samples to longitudinal clinical records is the model that global genomic research needs at scale, and Rwanda's infrastructure is among the first in Africa to achieve it systematically.
The Three Million African Genomes project (3MAG), proposed in a February 2021 Nature commentary by Professor Ambroise Wonkam of the University of Cape Town, aims to sequence the genomes of 3 million Africans within a decade. If achieved, it would transform the available reference data for African populations and dramatically accelerate both research and clinical application. The project requires sustained funding, political commitment, and expanded sequencing capacity, all of which remain challenges.
Why African genomics matters for global drug development
The commercial argument for investing in African genomic data is straightforward. Precision medicine, matching the right drug to the right patient based on genetic profile, only works if the genetic profiles of all patients have been characterised. A precision medicine framework built on European genomic data will fail to maximise efficacy and safety for African patients. As African pharmaceutical markets grow (Goldstein Research has projected the continental pharmaceutical market could reach USD 56 billion to USD 70 billion by 2030, up from USD 28.5 billion in 2017), companies that have invested in African-relevant genomic data will have a durable competitive advantage.
There is also a regulatory dimension. FDA diversity action plans, introduced under FDORA Section 3601, require sponsors to justify enrollment targets against disease epidemiology. For conditions with high African-ancestry prevalence, the absence of African genomic data will be increasingly difficult to defend in regulatory submissions. EMA's reflection paper on diversity in clinical trials sends the same signal. The diversity in clinical trials requirement is not separate from the genomics story; it is the same story, viewed from a regulatory rather than scientific angle.
Drug discovery offers a third argument. Novel drug targets, genes and pathways implicated in disease through GWAS, identified exclusively in European populations are systematically biased toward biology relevant to European patients. African GWAS have already identified novel hypertension loci, kidney disease variants, and metabolic disease associations not found in European studies. Pharmaceutical companies with access to African genomic data can identify targets invisible to competitors relying solely on European biobanks.
Gaps and challenges in genomics Africa research
Despite genuine progress, genomics in Africa faces persistent structural barriers that limit the pace and scale of scientific output.
Data sovereignty and benefit sharing remain live issues. Historical concerns about biological samples and genetic data leaving the continent without benefit to African populations or scientists are reflected in legislation now being introduced or developed across several African countries, restricting the export of biological samples and requiring data sharing agreements that include African institutions as full partners. Sponsors must engage with these requirements proactively.
Sequencing capacity is another constraint. Whole-genome sequencing remains expensive and requires specialised equipment, and most African countries lack on-site sequencing capacity at the scale needed for population studies, creating dependence on external facilities and raising logistics, cost, and data sovereignty concerns.
Bioinformatics workforce shortages remain despite H3ABioNet's training programmes. Analytical capacity limits the speed at which generated data can be translated into published findings and clinical insights.
Reference panels present a technical barrier. Many GWAS analysis tools and imputation servers are calibrated on European reference panels, which perform poorly when applied to African samples with different linkage disequilibrium patterns and variant frequencies. Africa-specific reference panels exist but are not yet comprehensive enough for all ancestry groups.
Under-sampling of rural populations is a further problem. Most African genomics studies have recruited from urban hospitals and research centres, which attract patients who are younger, better educated, and more economically stable than the general population. This sampling bias limits the generalisability of findings across African populations.
From data to discovery: the path forward
The next decade of African genomics research will be defined by scale, integration, and translation. Several developments will shape the trajectory.
Integration of genomic and phenotypic data is the immediate priority. Genomic data divorced from deep clinical records has limited utility. Linking whole-genome sequences to longitudinal electronic health records, capturing diagnosis, treatment, outcomes, and comorbidities, transforms genomic datasets from research curiosities into clinically actionable resources. Kapsule's infrastructure, which aggregates de-identified clinical records from facilities across 9 African countries, represents the phenotypic data layer that genomic research needs to achieve clinical relevance.
Expansion of the Three Million African Genomes initiative, combined with sustained investment in African sequencing infrastructure and bioinformatics training, would fundamentally shift the balance of global genomic data. If Africa moves from under 3 percent to 15 to 20 percent of global GWAS representation over the next decade, the impact on drug target identification, dosing guideline accuracy, and precision medicine implementation would be enormous, for African patients first, but ultimately for patients everywhere.
For sponsors and drug developers, the actionable step is engagement now. African genomics infrastructure is being built. The organisations that establish research partnerships, contribute to biobank development, and integrate African genomic data into their discovery and development programmes in the next three to five years will have assets that cannot easily be replicated later.
Kapsule provides access to structured, de-identified health records covering over 75 million patients across 9 African countries. Contact our team to discuss how phenotypic data from diverse African populations can complement your genomics research and drug development programmes.
This article is intended for informational purposes only and does not constitute legal, medical, or regulatory advice. Readers should obtain independent professional counsel for their specific circumstances.